Orion’s novel drug modality involves precision engineering ligands of small protein GPCRs, providing an enhanced solution to targeting previously-undrugged GPCRs. This approach is supported by one of the fastest drug discovery platforms in the industry and represents a large opportunity to discover and develop a new generation of GPCR-targeted medicines
Orion’s lead compound, OB-002, is a GPCR analog of CCL5 with best-in-class potency and a proven mechanism of action shown to have broad applicability across a range of serious diseases, including Cancer, Infectious Disease and Neuroinflammatory disorders.
Recognized
Leadership
Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),
You can find the investment blog – BestStocks.com – and their take on the potential of Orion’s technology in a recently published article here.
Ottawa, Canada, July 18, 2023 (GLOBE NEWSWIRE) — Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs),
343 Preston Street
11th floor,
Ottawa, On K1S 1N4
CANADA
+1 343.291.1032
Campus Biotech
Innovation Park
Avenue de Sécheron 15
1202 Genève
SWITZERLAND
Orion Biotechnology
Life Science Park
UI Bobrzyńskiego 14
30-348 Krakôw
POLAND
Leave us a message and we will try to respond by the next business day
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4
CANADA
info@orionbiotechnology.com
+1 343.291.1032
This website uses cookies to ensure you get the best experience on our site. By using this website, you agree to our use of cookies.
Leave us a message and we will try to respond by the next business day
343 Preston Street
11th floor,
Ottawa, ON K1S 1N4
CANADA
info@orionbiotechnology.com
+1 343.291.1032
